DK1254374T3 - Fremgangsmåde til diagnose af effektiviteten ved xenotype-antistofbehandling - Google Patents

Fremgangsmåde til diagnose af effektiviteten ved xenotype-antistofbehandling

Info

Publication number
DK1254374T3
DK1254374T3 DK01912066T DK01912066T DK1254374T3 DK 1254374 T3 DK1254374 T3 DK 1254374T3 DK 01912066 T DK01912066 T DK 01912066T DK 01912066 T DK01912066 T DK 01912066T DK 1254374 T3 DK1254374 T3 DK 1254374T3
Authority
DK
Denmark
Prior art keywords
antibody
patient
xenotypic
administration
level
Prior art date
Application number
DK01912066T
Other languages
Danish (da)
English (en)
Inventor
Antoine Noujaim
Original Assignee
Altarex Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altarex Medical Corp filed Critical Altarex Medical Corp
Application granted granted Critical
Publication of DK1254374T3 publication Critical patent/DK1254374T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK01912066T 2000-02-08 2001-02-08 Fremgangsmåde til diagnose af effektiviteten ved xenotype-antistofbehandling DK1254374T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18100800P 2000-02-08 2000-02-08
US20186800P 2000-05-04 2000-05-04
PCT/IB2001/000423 WO2001059452A2 (en) 2000-02-08 2001-02-08 Method for diagnosing efficacy of xenotypic antibody therapy

Publications (1)

Publication Number Publication Date
DK1254374T3 true DK1254374T3 (da) 2007-09-03

Family

ID=26876809

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01912066T DK1254374T3 (da) 2000-02-08 2001-02-08 Fremgangsmåde til diagnose af effektiviteten ved xenotype-antistofbehandling

Country Status (11)

Country Link
US (1) US20020022235A1 (de)
EP (1) EP1254374B1 (de)
JP (1) JP2003522774A (de)
AT (1) ATE360212T1 (de)
AU (2) AU4098201A (de)
CA (1) CA2399067A1 (de)
DE (1) DE60127935T2 (de)
DK (1) DK1254374T3 (de)
ES (1) ES2284624T3 (de)
PT (1) PT1254374E (de)
WO (1) WO2001059452A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003034977A2 (en) * 2001-10-26 2003-05-01 Altarex Medical Corp. Combination therapy for treating disease
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
US20060159688A1 (en) * 1996-05-15 2006-07-20 Ragupathy Madiyalakan Method for diagnosing efficacy of xenotypic antibody therapy
CA2481796A1 (en) * 2002-04-11 2003-10-23 Altarex Medical Corporation Binding agents and their use in targeting tumor cells
EP1578445A4 (de) * 2002-10-17 2007-04-04 Altarex Medical Corp Therapeutisches adjuvans

Also Published As

Publication number Publication date
AU2001240982B2 (en) 2006-05-04
DE60127935T2 (de) 2008-01-17
PT1254374E (pt) 2007-07-20
ATE360212T1 (de) 2007-05-15
ES2284624T3 (es) 2007-11-16
WO2001059452A2 (en) 2001-08-16
AU4098201A (en) 2001-08-20
EP1254374B1 (de) 2007-04-18
CA2399067A1 (en) 2001-08-16
WO2001059452A3 (en) 2002-07-18
DE60127935D1 (de) 2007-05-31
JP2003522774A (ja) 2003-07-29
EP1254374A2 (de) 2002-11-06
US20020022235A1 (en) 2002-02-21

Similar Documents

Publication Publication Date Title
ES2293973T3 (es) Anticuerpos anti-ccr2 humanizados y metodos de uso de los mismos.
DE60112744T2 (de) Diagnose, prophylaxe und behandlung von morbus crohn durch die verwendung des ompc antigens
BRPI0510274B8 (pt) uso de um agente para tratar ou prevenir doença celíaca, composição farmacêutica compreendendo dito agente, método de diagnóstico de doença celíaca, ou suscetibilidade à doença celíaca, uso do dito agente para a preparação de um meio de diagnóstico e kit para realizar o dito método de diagnóstico
DK0536275T3 (da) Tumorvækstinhibitorer udledt fra væv, fremgangsmåde til deres fremstilling samt anvendelse heraf
ATE283289T1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
DK1092155T3 (da) Fremgangsmåde til tidlig diagnose af carcinomer
WO2001075454A3 (en) Diagnosis and treatment of alzheimer's disease
DE60228557D1 (de) Candida-nachweis
DE59705683D1 (de) IMMUNOLOGISCHES NACHWEISVERFAHREN VON ANTIKÖRPERN, DIE GEGEN GEWEBE-TRANSGLUTAMINASE (tTG) GERICHTET SIND, VERWENDUNG VON tTG ZUR DIAGNOSE UND THERAPIEKONTROLLE SOWIE ORALES PHARMAZEUTISCHES MITTEL ENTHALTEND tTG
MY158262A (en) Diagnosis and treatments of cancers and other conditions
ATE480251T1 (de) Diagnose und behandlung von malignen neoplasmen
HUP0301877A2 (hu) Aromatáz inhibitorok és monoklonális anti-HER2 ellenanyagok mint tumorellenes szerek
ATE419516T1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
NO20010412L (no) Anvendelse av borreliacidal(e) epitoper av Borrelia burgdorferi ytre overflateprotein C som vaksine
BR0113213A (pt) Método para diagnosticar uma doença auto-imune, anticorpo, composição de diagnóstico, e, uso do anticorpo
MY142283A (en) Diagnosis and treatment of cancers and other conditions
ATE442439T1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
DK1520174T3 (da) Diagnostisk metode til bestemmelse af M. tuberculosis
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
NZ531712A (en) Reagents and methods for diagnosing, imaging and treating atherosclerotic disease
DK1254374T3 (da) Fremgangsmåde til diagnose af effektiviteten ved xenotype-antistofbehandling
TR200000181T2 (tr) Antikorların dahil olduğu, endokrin hücrelerine karşı aktivite gösteren ligandlar.
WO2004003155A3 (en) Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors
ATE408832T1 (de) Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper
WO2001077675A3 (en) Method for the prediction of preeclampsia and other diseases